<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794898</url>
  </required_header>
  <id_info>
    <org_study_id>P03027</org_study_id>
    <nct_id>NCT00794898</nct_id>
  </id_info>
  <brief_title>Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)</brief_title>
  <official_title>Onset of Efficacy of Anti-TNF Chimeric Monoclonal Antibody (Remicade) in the Treatment of Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label program of Remicade in the treatment of patients with active rheumatoid&#xD;
      arthritis (RA) despite treatment with methotrexate (MTX) to determine the onset of efficacy&#xD;
      of infliximab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2003</start_date>
  <completion_date type="Actual">April 1, 2004</completion_date>
  <primary_completion_date type="Actual">April 1, 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define the onset of efficacy of infliximab in patients with active RA, using the validated SF-36 questionnaire.</measure>
    <time_frame>After the first 2 weeks of treatment.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remicade in the treatment of patients with active RA despite treatment with MTX.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab (Remicade)</intervention_name>
    <description>Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Remicade</other_name>
    <other_name>SCH 215596</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, &gt;=18 to &lt;=75 years of age.&#xD;
&#xD;
          -  Diagnosis of RA according to the revised 1987 criteria of the American Rheumatism&#xD;
             Association (Arnett et al., 1988). The disease should have been diagnosed at least 6&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  Patients have active disease, in the opinion of the physician, despite the concomitant&#xD;
             use of DMARDS. Evidence of active disease may include any of the following:&#xD;
&#xD;
             6 or more swollen or tender joints; and 2 of the following&#xD;
&#xD;
               -  Morning stiffness &gt;45 minutes&#xD;
&#xD;
               -  C-reactive protein &gt;2.0 mg/L&#xD;
&#xD;
               -  ESR &gt;28 mm/h&#xD;
&#xD;
          -  Patients must have been using oral or parenteral MTX for at least 2 months with no&#xD;
             break(s) in treatment of more than 2 weeks total during this period. Patients must&#xD;
             have been on a stable dose of &gt;=7.5 mg/wk (IM, SQ, PO) for at least 8 weeks prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Men and women of childbearing potential must be using adequate birth control measures&#xD;
             (abstinence, oral contraceptives, IUD, barrier method with spermicide or, surgical&#xD;
             sterilization) and should continue such precautions for 6 months after receiving the&#xD;
             last infusion.&#xD;
&#xD;
          -  Patients must be on a stable dose of folic acid prophylaxis for at least 4 weeks prior&#xD;
             to Screening.&#xD;
&#xD;
          -  Patients using oral corticosteroids or NSAIDs, must have been on a stable dose for at&#xD;
             least 4 weeks prior to Screening, and must continue during the treatment period. If&#xD;
             currently not using corticosteroids or NSAIDs, the patient must have not received&#xD;
             corticosteroids or NASIDs for at least 4 weeks prior to Screening.&#xD;
&#xD;
          -  Patients must be able to adhere to the program visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Patients must be capable of giving informed consent and the consent must have been&#xD;
             obtained prior to any screening procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, nursing mothers or a planned pregnancy within 1.5 years of enrollment&#xD;
&#xD;
          -  Patients who are incapacitated, largely or wholly bedridden or confined to a&#xD;
             wheelchair, and who have little or no ability for self-care.&#xD;
&#xD;
          -  Patients who have any current systemic inflammatory condition with signs and symptoms&#xD;
             that might confound the evaluations of benefit from the Remicade therapy, eg, Lyme&#xD;
             disease, or a rheumatic disease other than RA.&#xD;
&#xD;
          -  Use of DMARDS other than MTX within 4 weeks prior to Screening.&#xD;
&#xD;
          -  Use of intra-articular, IM, or IV. corticosteroids (including IM ACTH) within 4 weeks&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Prior administration any other therapeutic agent targeted at reducing TNF (eg,&#xD;
             Etanercept, pentoxifylline, thalidomide or anti-CD4+ antibody) within the previous 6&#xD;
             months.&#xD;
&#xD;
          -  Treatment with any investigational drug within the previous 6 months.&#xD;
&#xD;
          -  A history of known allergies to murine proteins.&#xD;
&#xD;
          -  Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3&#xD;
             months. Less serious infections in the previous 3 months, such as acute upper&#xD;
             respiratory tract infection (colds) or uncomplicated urinary tract infection need not&#xD;
             be considered exclusions at the discretion of the treating physician.&#xD;
&#xD;
          -  History of opportunistic infections such as herpes zoster within 2 months of&#xD;
             Screening. Evidence of active CMV, active pneumocystis carinii, drug resistant&#xD;
             atypical mycobacterium, etc.&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,&#xD;
             hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease.&#xD;
&#xD;
          -  Any currently known malignancy or pre-malignant lesions or any history of malignancy&#xD;
             within the past 5 years.&#xD;
&#xD;
          -  Patients with alcoholism, alcoholic liver disease, or other chronic liver disease.&#xD;
&#xD;
          -  Patients with a positive PPD within 3 months and chest X-Ray suggestive of active TB&#xD;
             or a previous exposure to TB.&#xD;
&#xD;
          -  Patients with CHF, even if asymptomatic or not requiring medication must be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

